As a reminder, U.S. Federal Physician Payments Sunshine Act (Open Payments) reports are due March 31. There are also state and municipal deadlines that have either passed or are coming up, including:
- January 1:
- Vermont: submit Compliance Officer Form
- California: post compliance declaration on website (annually, no due date)
- Massachusetts: perform annual audit during year
- AdvaMed: make certification (optional)
- January 15
- Nevada: submit list of pharmaceutical sales representation
- Miami-Dade County, Florida: register/renew sales representatives annually
- Chicago: register/renew pharmaceutical sales representatives annually
- March 1
- Nevada: make pharmaceutical sales report disclosure
- March 31
- Federal: submit Physician Payments Sunshine Act (Open Payments) reports
- April 1
- Vermont: submit disclosure report
- Vermont: submit sample report
- Nevada: submit drug pricing and sales report
- Federal: submit drug sample report
- May 1
- Nevada: perform annual audit during year (covering May 1 – April 30)
- Minnesota: submit payments to practitioners report
- June 1
- Nevada: submit compliance form (AB128 certification)
- July 1
- Massachusetts: submit marketing disclosure report
- Connecticut: report payments to advanced practice registered nurses
- Miami-Dade County, Florida: submit sales representative expenditure reports
- Washington, D.C.: submit sales representative reports (also, register representatives every 2 years)
- August 31
- Massachusetts: registration and filing renewal (generally between early July and late August)
For more information and a survey of international requirements, visit our website.
New FDA Commissioner?
Who will be the permanent FDA Commissioner? Currently, Janet Woodcock, M.D., a long-standing, well respected FDA official, and former Director of the Center for Drug Evaluation and Research (CDER), is the Acting Commissioner. A recent letter to President Joe Biden, penned by six former FDA commissioners stops short of endorsing Dr. Woodcock as permanent Commissioner, but applauds her leadership. The letter is at the very least a tacit endorsement for making Dr. Woodcock FDA Commissioner. Former FDA Commissioners that signed off on the letter include Robert Califf, MD, Scott Gottlieb, MD, Margaret Hamburg, MD, Jane Henney, MD, and Mark McClellan, MD. Despite this, Acting Commissioner Woodcock is facing criticism for approving opioids during her time at the helm of CDER. Another FDA official, Joshua Sharfstein, MD, is also considered a candidate for the position, although some argue his luster, like Woodcock’s has faded. Others predict that neither Woodcock nor Sharfstein will get the job and that President Biden is looking outside of the Agency. We still view Dr. Woodcock as the lead candidate for the role. Time will tell.
Our Team Is Growing
Brynn specializes in counseling medical technology and pharmaceutical companies on FDA law and regulations. She possesses deep expertise in quality system compliance and remediation. She started her career at Boston Scientific as a design assurance engineer and from there worked in advancing engineering roles at St. Jude Medical (Abbott), American Medical Systems (Boston Scientific), Covidien-Medtronic, and most recently at Monteris Medical. Brynn is an Adjunct Professor of Law at Mitchell Hamline School of Law (St. Paul, MN) where she teaches Drug & Device Law.
Paul specializes in privacy compliance matters including HIPAA, GDPR, and other state and international privacy laws. Prior to practicing at Gardner Law, Paul worked in Privacy and Data Protection at Medtronic. counseling on privacy issues for medical technology companies and other health care organizations. Before that, Paul was an Associate General Counsel for the State of Minnesota.
Nate focuses on counseling medical technology and pharmaceutical companies on FDA regulatory/submissions work and copy review. Before practicing at Gardner Law, Nate was at Medtronic where he held the position of Principal Regulatory Affairs Specialist. Prior to that, Nate was a Law Clerk at the Colorado 2nd Judicial District Court and a Research Associate at R&D Systems (Bio-Techne).
Tim Philips is a quality assurance and regulatory affairs professional with over 30 years of experience in commodities regulated by the U.S. Food & Drug Administration (FDA). He is an expert and instructor in FDA law / regulation, quality systems, inspections, evidence development, enforcement actions, and product recalls with an emphasis on post-market compliance of medical devices. Tim is an Adjunct Professor at the University of St. Thomas (St. Paul, MN) in the Regulatory Science Program in the School of Engineering.
We recently updated our website to include more content. Visit GardnerLaw.com to read contemporary industry news and learn about our practice areas, including: Compliance, Ad Promo Review, Sunshine Reporting, Regulatory, Quality, Enforcement, Clinical, and Privacy.
Recent Topics We’ve Reported On
OIG issued a Special Fraud Alert that applies to pharmaceutical and medical technology company-sponsored speaker programs.
Last fall we held a complimentary 4-part webinar series tailored to MedTech and Pharma companies. Watch presentations by U.S. and E.U. attorneys and download the slides.
- Privacy (GDPR, CCPA, HIPAA)
- Regulatory (EUA, MDR)
- Health Care Compliance (Virtual Detailing, Recent Cases, Sunshine, Speaker Program Fraud Alert)
- Due Diligence for Buyers and Sellers (U.S./E.U.)
- Mark Gardner, M.B.A., J.D., Managing Attorney, Gardner Law
- Dr. Cord Willhöft, LL.M., Partner, Life Sciences, Fieldfisher
- Amanda Johnston, J.D., R.A.C., Sr. Attorney, Gardner Law
- Oliver Süme, Partner, Technology, Outsourcing and Privacy, Fieldfisher
- Brynn Stanley, J.D., Associate Attorney, Gardner Law
- Dr. Andreas Driver LL.M., Partner, Corporate
- Heather Potter, J.D.,CIPP/E, Counsel, Gardner Law
The Court of Justice for the European Union recently invalidated the EU-US Privacy Shield, a mechanism relied upon by many companies to ensure adequate safeguards for the cross-border transfer of EU citizen data. This recent ruling has left many companies—including medical technology and pharmaceutical companies with EU operations, such as sales, marketing, manufacturing, and/or clinical activities—scrambling and confused.